Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases

Marloes A. H. M. Michels1, Nicole C. A. J. van de Kar1, Marcin Okrój2, Anna M. Blom3, Sanne A. W. van Kraaij4, Elena B. Volokhina1,4† and Lambertus P. W. J. van den Heuvel1,4,5*†

On Behalf of the COMBAT Consortium

1Department of Pediatric Nephrology, Radboud Institute for Molecular Life Sciences, Arminia Children’s Hospital, Radboud University Medical Center, Nijmegen, Netherlands, 2Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland, 3Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden, 4Department of Pediatrics/Pediatric Nephrology and Department of Development and Regeneration, University Hospitals Leuven, Leuven, Belgium

Overactivation of the alternative pathway of the complement system is associated with the renal diseases atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). C3 nephritic factors (C3NeF) play an important role in C3G pathogenesis by stabilizing the key enzymatic complex of complement, the C3 convertase. However, the reliability of assays detecting these autoantibodies is limited. Therefore, in this study, we validated and optimized a prototype hemolytic method for robust detection and characterization of factors causing convertase overactivity in large patient cohorts. The assay assesses convertase activity directly in the physiological milieu of serum and therefore is not restricted to detection of stabilizing autoantibodies such as C3NeF but may also reveal genetic variants resulting in prolonged convertase activity. We first defined clear cutoff values based on convertase activity in healthy controls. Next, we evaluated 27 C3G patient samples and found 16 positive for prolonged convertase activity, indicating the presence of factors influencing convertase stability. In three patients, the overactive convertase profile was persistent over disease course while in another patient the increased stability normalized in remission. In all these four patients, the convertase-stabilizing activity resided in the purified immunoglobulin (Ig) fraction, demonstrating the autoantibody nature. By contrast, the Igs of a familial aHUS patient carrying the complement factor B mutation p.Lys323Glu did not reveal convertase stabilization. However, in serum prolonged convertase activity was observed and segregated with the mutation in both affected and unaffected family members. In conclusion, we present a robust and reliable
INTRODUCTION

The complement system, a cornerstone of innate immunity, provides the body with protection against invading pathogens and dangerous host cells (1, 2). The system can be activated via three pathways—the classical, lectin and alternative pathway (AP)—depending on the initial trigger that is encountered. All pathways converge at the central event of complement activation: the cleavage of C3 by C3 convertases. This enzymatic reaction supports further activation of the complement cascade with the release of various anaphylatoxins and opsonins, and eventually the formation of the membrane attack complex (MAC). These events all contribute to inflammation, phagocytosis and the damage of susceptible targets (1–3).

In contrast to the classical and lectin pathway, which are only activated upon pattern recognition, the AP is continuously mildly activated and therefore specifically serves as a surveillance mechanism. C3 is subjected to spontaneous hydrolysis of its internal thioester bond at a very low rate, and this generates the active C3(H2O) molecule. Hydrolyzed C3 can bind to complement factor B (FB), which is subsequently cleaved by complement factor D (FD) to form an initial, fluid phase AP C3 convertase, C3(H2O)Bb, that is capable of converting native C3 into the active C3a (anaphylatoxin) and C3b (opsonin) fragments. This mechanism providing a persistent low level of active C3 in the blood is known as “tick-over” and allows constant responsiveness to potential danger. Besides the tick-over mechanism, the AP may also be initiated by C3 convertases of the classical and lectin pathway that generate active C3b (1, 4, 5). Furthermore, C3 may be cleaved into C3b by certain non-specific proteases, especially at sites of inflammation, coagulation, and infection (6).

Activated C3b molecules expose a reactive thioester moiety via which they can subsequently bind to hydroxyl or amino groups on target surfaces in close proximity to the activation site. This C3b binding, and thus initiation of AP activity, is preferentially triggered by certain carbohydrate structures on microbes and other foreign surfaces, e.g., LPS and zymosan. By interacting with FB and FD, target-bound C3b can subsequently form new surface-bound convertases (C3bBb) that can be further stabilized by properdin (C3bBbP). Properdin has also been proposed to act as a pattern recognition molecule able to initiate the AP on certain targets by recruiting C3b and FB. Once formed, AP C3 convertases can massively amplify the immune response by converting more C3 molecules into C3b, which in turn support new convertase formation. Incorporation of C3b into existing C3 convertases generates C5 convertases (C3bBbC3b), which cleave C5 into the potent anaphylatoxin C5a and the fragment C5b that initiates the assembly of the MAC (C5b-9) complex. The amplification loop of the AP can also be induced by C3b molecules generated by C3 convertases from the other two activation pathways. In this way, the AP can account for over 80% of total complement activity. Thus, besides being a surveillance system, the AP acts as an important amplifier of initiated complement responses (1, 4, 5).

The powerful action of the AP requires sophisticated regulation to prevent damage by excessive activation or self-attack. Therefore, human cells express membrane-bound complement inhibitors, including decay-accelerating factor (DAF), membrane cofactor protein (MCP), and complement receptor 1 (CR1). Together with the soluble regulatory proteins complement factor H (FH) and complement factor I (FI), which can act in fluid phase or can be recruited to surfaces, these complement regulators prevent the formation of potent C3 convertases on healthy host surfaces and keep AP activity in control. The inhibitors of the C3 convertase can act via two ways. The first is by accelerating the convertase decay and is fulfilled by DAF, CR1, and FH. These regulators can also compete with FB for binding to C3b and thereby inhibit new convertase formation. The second is by preventing convertase formation via acting as cofactors for FI-mediated inactivation of C3b. This action is supported by MCP, CR1, and FH (7–9). However, genetic aberrations in complement genes and/or autoantibodies against complement components may, in combination with triggering events, disturb this sophisticated regulation, causing overactivation of the system. A dysregulated AP has been particularly associated with the renal diseases the atypical hemolytic uremic syndrome (aHUS) and the disease entity C3 glomerulopathy (C3G) (10–15).

C3 glomerulopathy is a recently defined umbrella classification for severe renal diseases that are characterized by C3 accumulation in the glomeruli without or with sparse immunoglobulin (Ig) deposition. The main two diseases encompassed by C3G are dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) (16). Up to 50% of patients progress to end-stage renal disease within 10 years after first presentation (17). The most important pathogenic factors in C3G are autoantibodies against the C3 convertase of the AP named C3 nephritic factors (C3NeF), although pathogenic variants in complement genes have also been reported (14, 15). By binding to neoepitopes of the formed C3bBb(P), C3NeF stabilizes the otherwise labile convertase and thereby prolongs its half-life (18). C3NeF has been detected in approximately 80–90% of DDD patients (15, 19, 20) and in 40–50% of patients with C3GN (15, 21).

Atypical HUS is a form of thrombotic microangiopathy and is not associated with C3NeF, but pathogenic mutations in complement genes or autoantibodies against FH are the most common cause of improper complement regulation (22–25). Blocking
C5 and terminal pathway activation with the C5-directed antibody eculizumab is a very effective treatment for this disease. Eculizumab became the first approved complement-inhibiting drug for aHUS in 2012 (26, 27). By contrast, trials of eculizumab treatment in C3G patients have shown contradicting outcomes so far. Thus, the value of eculizumab as a therapy for C3G requires further investigation (17, 28, 29).

Detection of C3NeF is not only helpful in diagnosis of C3G but also in choice of therapy for the patient, especially in the light of upcoming complement-inhibiting strategies. Nevertheless, a robust and reproducible method for C3NeF detection is still lacking. A recent European quality assessment round reported a success rate of only 50% among the participating laboratories (30). This also hampers our understanding of the exact role of C3NeF in C3G pathogenesis. C3NeF are functionally heterogeneous (31) and conflicting associations have been found between its presence and the patient’s disease state and progression (20, 32–34). Some reports even describe C3NeF in healthy individuals (35, 36).

Recently, we described a new hemolytic method for measurement of convertase activity in the physiological milieu of whole serum. This assay allows the robust detection of factors prolonging convertase stability in a direct way, such as C3NeF, and/or in an indirect way by impairing the regulation of the convertase (37). For convenience, we will use the term convertase-stabilizing factors for both these types of factors, which are either directly or indirectly prolonging the convertase half-life. The assay uses C5-blocking agents [eculizumab or the tick protein Ornithodoros moubata complement inhibitor (OmCI) (37, 38)] to strictly separate the complement cascade into two steps: the formation of C3/C5 convertases by test sera in a first step and the formation of lytic MAC complexes in a standardized second step for readout. Dynamics of convertase assembly and decay in the first step are then monitored in time. In this work, we further modified this convertase activity assay to screen for convertase-stabilizing factors in patient cohorts by defining clear cutoff criteria based on healthy controls. In addition, we showed expanded analysis of clinical samples with different types of convertase-stabilizing factors and their presence over disease course.

MATERIALS AND METHODS

Sample Collection
Whole blood was obtained from patients and healthy controls and processed within 1 h after sampling. For serum, blood was allowed to clot at room temperature for 30–45 min followed by centrifugation (10 min, 2,500 g, 4°C). To obtain plasma, blood was drawn into tubes with the anticoagulant ethylenediamine-tetraacetic acid (EDTA) that were immediately placed on ice and subsequently centrifuged according to the same procedure. Afterward, the serum and EDTA plasma fractions were collected, aliquoted, and stored at −80°C until use. For the healthy controls, following exclusion criteria were applicable: fever, bacterial/viral infection in previous 2 weeks, chronic illness, inherited or acquired immune disorders, and immunosuppressive medication. In addition, pooled normal human serum (NHS) and pooled normal human plasma (NHP) were made by pooling 15 and 12 individual control samples, respectively. This study was carried out in accordance with the recommendations of the appropriate version of the Declaration of Helsinki. All subjects gave written informed consent, and the protocol was approved by the ethical committee of the Radboud University Medical Center (FH 06979).

Erythrocyte Working Suspensions
Rabbit erythrocytes (RbE) in Alsever’s solution were obtained from Envigo (Venray, the Netherlands). The working suspensions of RbE were prepared by washing them with magnesium–ethylene glycol tetraacetic acid (Mg–EGTA) buffer (2.03 mM veronal buffer, pH 7.4, 10 mM EGTA, 7 mM MgCl2, 0.083% gelatin, 115 mM d-glucose, and 60 mM NaCl) until there was no visible hemoglobin left in the supernatant. To standardize the number of erythrocytes in each experiment, these working suspensions were calibrated so the absorbance measured at 405 nm of 10× diluted erythrocytes in water was between 0.8 and 1.2.

Ig Purification
The Ig fractions from NHP and from the EDTA plasma of patients P24, P25, P26, and P27 (Table 1) were isolated by affinity purification using NAB™ protein A/G 5 mL spin columns (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. In short, 0.85–1.0 mL of EDTA plasma was diluted with binding buffer (0.1 M phosphate, 0.15 M sodium chloride, and pH 7.2) to 10 mL and loaded on the columns. Unbound fractions were washed with binding buffer, and thereafter bound Igs were eluted using 0.1 M glycine, pH 2.5 followed by immediate neutralization with 1/10 volume 1 M Tris, pH 8.5. Subsequently, Ig fractions were dialyzed against phosphate buffered saline using SnakeSkin® dialysis tubes (Thermo Fisher Scientific, Waltham, MA, USA) with a 10 kD molecular weight cutoff and concentrated to the initial plasma sample volume using Amicon® Ultra-15 centrifugal filter devices (Merck Millipore, Billerica, MA, USA) with similar cutoff. Total protein concentrations in these samples were measured using NanoDrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and varied between 4.73 and 12.48 mg/mL, which are within the normal range for Igs.

Convertase Activity Assay
Detection of AP convertase-stabilizing factors in human serum was achieved using a two-step hemolytic assay as previously described (37) and as further specified in Figure 1. Briefly, per experimental time point 10 µL of prepared RbE were mixed with 20 µL Mg–EGTA containing 150 nM of the C5 inhibitor eculizumab (Alexion Pharmaceuticals, Cheshire, CT, USA), after which at different time points an additional 20 µL Mg–EGTA containing test serum or Ig fractions mixed 1:1 with NHS was added for convertase assembly (5, 10, 15, 20, 30, 40, 50, or 60 min). Final concentrations of serum were optimized per batch of erythrocytes and were generally 3.75 or 5%. Subsequently, cells were washed with 150 µL 40 mM EDTA–gelatin veronal buffer (EDTA–GVB, 4.41 mM veronal buffer, 0.1% gelatin, 130 mM NaCl, pH 7.4) and collected by centrifugation (2 min, 1,000 g, room temperature).

Frontiers in Immunology | www.frontiersin.org April 2018 Volume 9 Article 612
### TABLE 1 | Clinical and genetic data.

| Patient/subject | Gender (M/F) | Age at time of study (years) | Diagnosis | Genetic aberrations\(^b\) | Convertase-stabilizing factors present (Y/N) | C3 levels\(^g\) (mg/L; 700–1500) |
|-----------------|--------------|-----------------------------|-----------|--------------------------|---------------------------------------------|---------------------------------|
| **(a) C3G cohort** | | | | | | |
| P1              | M            | 63                          | DDD       |                          | N                                           | NA                             |
| P2              | M            | 10                          | C3GN      |                          | N                                           | NA                             |
| P3              | M            | 66                          | C3GN      |                          | N                                           | 588                            |
| P4              | M            | 52                          | DDD       | C3 c.26T>C (p.Leu9Pro)\(^d\) located in signal sequence | N                                           | NA                             |
| P5              | M            | 43                          | C3GN      | N                        | Normal                                      | 941                            |
| P6              | F            | 42                          | C3GN      | N                        | Normal                                      | 660                            |
| P7              | M            | 37                          | C3GN      | N                        | NA                                          | 530                            |
| P8              | F            | 33                          | C3G\(^a\) | N                        | Normal                                      | 102                            |
| P9              | M            | 6                           | DDD       | N                        | 644                                         | NA                             |
| P10             | M            | 9                           | C3G\(^a\) | NA                       | 360                                         | NA                             |
| P11             | M            | 11                          | C3GN      | N                        | 650                                         | NA                             |
| P12             | F            | 44                          | C3GN      | N                        | 530                                         | NA                             |
| P13             | M            | 7                           | DDD       | CFI c.1217G>A (p.Arg406His)\(^f\) (39) | Y                                           | Decreased                      |
| P14             | F            | 19                          | C3G\(^a\) | CFH c.2850G>T (p.Gln950His)\(^f\) (15), (40) | Y                                           | NA                            |
| P15             | M            | 27                          | C3GN      | C3 c.962G>A (p.Gly321Glu)\(^f\) | Y                                           | NA                            |
| P16             | F            | 6                           | C3GN      | CFH full length deletion\(^f\) (39) | Y                                           | 500                            |
| P17             | F            | 7                           | C3G\(^a\) | Y                        | NA                                          | NA                             |
| P18             | M            | 10                          | C3GN      | Y                        | 220                                         | NA                             |
| P19             | M            | 7                           | DDD       | Y                        | 210                                         | NA                             |
| P20             | F            | 9                           | DDD       | Y                        | 100                                         | NA                             |
| P21             | F            | 7                           | DDD       | Y                        | 510                                         | NA                             |
| P22             | M            | 5                           | DDD       | Y                        | 110                                         | NA                             |
| P23             | M            | 15                          | C3GN      | Y                        | NA                                          | NA                             |
| P24             | F            | 8                           | C3GN      | CFHRS5 c.542G>C (p.Arg181Thr)\(^f\) | Y                                           | 110                            |
| P25             | M            | 9                           | DDD       | Y                        | 82                                          | NA                             |
| P26             | F            | 5                           | C3GN      | Y                        | 830                                         | NA                             |
| P27             | M            | 15                          | C3GN      | Y                        | 70                                          | NA                             |

| **(b) Family with complement factor B mutation and aHUS** | | | | | | |
| II. 5           | M            | 41                          | –         | N                        | N                                           | N                              |
| II. 6           | F            | 40                          | –         | CFB c.967A>G (p.Lys323Glu)\(^f\) (41, 42) | Y                                           | NA                            |
| III. 1          | F            | 22                          | –         | N                        | N                                           | NA                            |
| III. 2          | M            | 18                          | –         | N                        | N                                           | NA                            |
| III. 4          | F            | 14                          | aHUS      | CFB c.967A>G (p.Lys323Glu)\(^f\) (41, 42) | Y                                           | NA                            |
| III. 5          | F            | 7                           | –         | N                        | N                                           | NA                            |
| III. 6          | F            | 4                           | aHUS      | CFB c.967A>G (p.Lys323Glu)\(^f\) (41, 42) | Y                                           | 260                            |

\(^a\)No distinction possible into C3GN or DDD, since no electron microscopy was performed or no data available.

\(^b\)All genetic variants found were heterozygous.

\(^c\)To the best of our knowledge, not previously reported in context of C3G.

\(^d\)Previously reported in a DDD patient.

\(^e\)Previously reported in C3GN patients.

\(^f\)Previously reported in aHUS patients.

\(^g\)C3 levels were measured by nephelometry with the normal range indicated between brackets. Data given are those available as closest to the time of convertase activity assessment. For samples obtained from peripheral centers and from which C3 data were accessible, results are presented as “normal” or “decreased” since normal ranges vary between centers.

\(a\)HUS, atypical hemolytic uremic syndrome; C3G, C3 glomerulopathy; C3GN, C3 glomerulonephritis; DDD, dense deposit disease; NA, not available.

---

Thereafter, cells were incubated for 60 min with 50 µL of 2.5% guinea pig serum (Envigo, Venray, the Netherlands) in EDTA–GVB and another 50 µL of Mg–EGTA buffer to develop MAC and subsequent hemolysis. All incubation steps were performed at 37°C, with 600 rpm agitation in a VWR® Incubating Microplate Shaker with 3 mm orbit (VWR International, Radnor, PA, USA) in V-shaped 96-well plates (Greiner Bio-One, Kremsmünster, Austria). Finally, supernatant was collected by centrifugation and transferred to flat-bottom 96-well plates (Greiner Bio-One, Kremsmünster, Austria). Hemolysis was quantified as percentage of full lysis by an equal amount of erythrocytes in water: (A\(_{405}\) test sample − A\(_{405}\) blank)/(A\(_{405}\) full lysis − A\(_{405}\) blank) × 100.

### Statistical Analysis
Where indicated, data were analyzed using two-way analysis of variance with Bonferroni’s post test using GraphPad Prism 5.03 for Windows (GraphPad Software, San Diego, CA, USA).

### RESULTS

#### Study Cohort
A group of 27 patients diagnosed with C3G and referred to the Radboud University Medical Center were included in the study. Diagnosis was suspected based on presence of clinical features such as...
as hypertension, proteinuria, and nephrotic/nephritic syndrome, possibly combined with low serum C3. Diagnosis was confirmed after pathological judgment of renal biopsy following the recommendations defined in the consensus report of the first C3G Meeting (16). Subdivision of C3G into C3GN and DDD was solely based on electron microscopy appearance. In total, 9 patients were diagnosed with DDD, 14 with C3GN, and in 4 patients no distinction between the C3G subforms could be made since data required for subdivision were not available. In this C3G cohort (age range: 5–66 years; 17 children, 10 adults), no FH autoantibodies (FHAb) were detected, and 6 patients carried mutations in complement (regulating) genes (Table 1a). Besides samples from C3G patients, sera from a female patient with familial aHUS and six of her affected and non-affected family members were available for analysis. In total, three of these family members were carrier of the heterozygous FB p.Lys323Glu mutation and two of them were also affected with aHUS (Table 1b).

**Convertase Activity in Healthy Donors**

To define normal convertase activity, we tested the sera of 15 healthy controls (Figure 2). Due to low serum C3 levels in vivo,
many C3G samples show low hemolytic activity. To compensate for this possible complement consumption, all samples in this study, including those from controls, were diluted 1:1 with NHS. We previously showed that this approach restored hemolytic activity while still allowing the detection of convertase-stabilizing factors in patient serum (37) (also see Figure S1 in Supplementary Material). The convertase activity profiles of healthy controls demonstrated a constant pattern, which was comparable to that of NHS. Convertase activity reached its maximum after 10–15 min of incubation, and at 30 min activity returned to background levels in all control samples.

The ratio between the highest achieved hemolysis (top) and the lysis at the point at which controls have returned to background levels, in this case at $t = 30 \text{ min}$ ($t_{30}$), was $5.4 \pm 2.7$ (mean $\pm 2$ SD) for healthy controls. Prolonged convertase activity, i.e., delayed decay, was defined as a top/$t_{30}$ ratio below the mean $- 2$ SD of controls, here $<2.7$. Because samples with a low hemolytic activity overall are also likely to be positive for this criterion, only samples that have a total area under the curve equal to or higher than that of NHS are considered positive.

**Convertase Activity in Patients**

Next, we analyzed convertase activity in the cohort of 27 C3G patients. Samples were first screened at $t_{30}$ in a single time point screening (Figure 3A). The 21 samples that at $t_{30}$ showed lysis above that of NHS (18.7%) were selected for further analysis of convertase activity over time. All other samples were considered negative for the presence of convertase-stabilizing factors.

Of the 21 patients who were selected for analysis of the convertase activity profile, 16 showed a top/$t_{30}$ ratio below 2.7 (Figure 3B). These samples were considered positive for convertase-stabilizing factors. The other five samples, selected in the initial screening as possibly positive, did not meet these criteria and were therefore considered to have normal convertase activity profiles (Figure 3C).

**Convertase Activity Over Disease Course**

Subsequently, we investigated whether convertase activity profiles could change over disease course. From four patients who showed increased convertase stability, P24–P27 (Table 1), serum samples were available derived over different periods of their disease, e.g., from active disease states and/or (partial) remission periods. The active disease state samples of P24 and the active disease and partial remission samples of P27 all displayed prolonged convertase activity (Figures 4A,B). Also P25 showed a persistent stabilized convertase profile in both active disease and in partial and complete remission (Figure 4C). By contrast, the prolonged convertase activity shown for P26 was only detected in the acute phase and normalized in remission (Figure 4D).

**Prolonged Convertase Activity due to Autoantibodies**

For these four patients, we then investigated whether the convertase-stabilizing effect was due to autoantibodies such as C3NeF (Figure 5). To this end, the Ig fractions from these patients were purified using protein A/G affinity chromatography. Samples were concentrated in phosphate buffered saline to the initial plasma sample volume. Addition of an equal volume of the purified Ig fractions to NHS revealed comparable stabilizing effects on the convertases as seen for these patient’s serum samples. This stabilization could not be observed when healthy control Igs were added to NHS. Thus, in these patients prolonged convertase activity could be attributed to autoantibody activity.

**Prolonged Convertase Activity due to FB Mutation in aHUS Family**

Previously, we described prolonged convertase activity in the serum of an aHUS patient carrying the p.Lys323Glu mutation in FB (37). In this study, we analyzed convertase activity in available serum samples of affected and unaffected family members of this patient (Figure 6A). Stabilized convertase profiles segregated with the FB mutation in both affected and non-affected family members (Figure 6B). When purified total Igs of the index patient were added to NHS, no stabilization of the C3 convertase could be observed (Figure 6C), unlike Ig fractions from C3G patients (Figure 5). This indicates that in these individuals, prolonged convertase activity could be attributed to the FB mutation rather than to autoantibody activity.

**DISCUSSION**

Previously, we described proof-of-concept of a robust method to measure C3 convertase activity allowing detection of factors influencing convertase activity in whole serum. Here, we further standardized assay conditions for screening in patient cohorts and for critical evaluation of convertase-stabilizing factors in clinical samples.

We showed low variation among healthy controls in the assay (Figure 2) and based on this defined clear cutoff criteria for assessing the presence of convertase-stabilizing factors in patient samples. The samples were considered positive when they showed a top/$t_{30}$ ratio lower than the mean $- 2$ SD of healthy controls.
controls in their convertase activity profile. Cutoff values have to be evaluated for each laboratory individually. When large cohorts of patients have to be analyzed, the samples may be first screened for high lysis at a single time point (e.g., t_{30}) and compared with NHS (Figure 3A). This efficient approach allows to save both time and patient material, but we underline that it should supplement and not replace the evaluation of a complete convertase activity profile to confirm positivity. In this work, we only used serum samples to assess convertase activity, but from our unpublished data we know that EDTA plasma samples may be used as well; no complement-inhibiting effects of EDTA are observed under the described test conditions (Figure S2 in Supplementary Material).

Furthermore, as an alternative for eculizumab, which is expensive and may be difficult to access, the tick protein OmCI [or its commercially available variant Coversin (43)] may be used for C5 blockage in the first step of the assay (37, 38). Future research may benefit from cheaper alternative C5-blocking agents.

The positive samples showed high variation in the degree of convertase stabilization: where some sera showed active convertases up to t_{60} other sera showed delayed decay with breakdown of convertases between 30 and 60 min (Figure 3B).

First of all, this may be attributed to the heterogeneity of C3NeF autoantibodies, which recognize different neoepitopes of the convertase complex. All C3NeF prevent the natural intrinsic decay of the convertase (44), but they vary in the degree of resistance they provide against extrinsic decay mediated by complement regulators (31, 44–47). Two reports described C3NeF that were completely unable to interfere with complement regulators and the authors indicated them as likely less pathogenic in vivo, since patients with these C3NeF did not present with hypocomplementemia (31, 47). Besides, the interaction of C3NeF with the convertase can be dependent on properdin or be independent of this positive complement regulator. Properdin-dependent and -independent C3NeF types may differ in the degree of convertase stabilization they provide (31) and have been related to different degrees of terminal pathway activation observed in patients (48, 49). A recent study identified properdin-dependent C3NeF as C5NeF: nephritic factors stabilizing C5 convertases (50). Since in our assay whole serum conditions are used in which properdin is present, our assay should be able to detect those factors as well. Furthermore, few previous reports described autoantibodies against the individual components of the convertase, i.e., FB and...
C3b, which may also increase the convertase half-life (19, 51–53). However, not much is known of the role of these autoantibodies and their occurrence in C3G patients, which tends to be lower than the occurrence of C3NeF (19, 52). In addition, our previous work indicated that samples of aHUS patients positive for FHAAb may also show C3NeF-like stabilizing activity in the assay (37). In this cohort, we also checked for presence of FHAAb, but no patients were found positive. In conclusion, this variety in factors influencing convertase activity via different mechanisms may reflect the heterogeneity of the stabilized convertase activity profiles in our cohort. To distinguish between these factors, additional methods using purified components, e.g., enzyme-linked immune sorbert assay (ELISA) techniques, are needed.

In total, 16 out of the 27 patients (59%) of the C3G cohort were positive in this assay (Figure 3B); 67% positive in DDD patients, 57% in the C3GN patients, and 50% in the C3G patient group that could not be subdivided into DDD or C3GN. Of these 16, 13 were children and 3 were adults. Considering that of all convertase-stabilizing factors described earlier C3NeF is most common in C3G, our data are in line with the numbers of C3NeF positive patients reported by other studies (15, 19–21, 54).

Commonly used assays for C3NeF are often based on studying isolated interactions of C3NeF with convertases assembled out of purified proteins on artificial surfaces (ELISA) or on sheep erythrocytes (semiquantitative hemolytic assay). In contrast to RbE, these do not naturally activate the AP and therefore require complex and time-consuming steps to build up the enzyme. Furthermore, in some studies, different detection assays were used alongside each other. Patients can be variably positive in these different assays, again indicating the heterogeneous nature of C3NeF (19, 31).

An important advantage of our method is the direct assessment of convertase stability in whole, unhandled serum, which
Identification of convertase-stabilizing factors in immunoglobulin (Ig) fractions of patients with C3 glomerulopathy. Serum samples of P24 (A), P27 (B), P25 (C), and P26 (D) were tested mixed 1:1 with pooled normal human serum (NHS) to a final concentration of 5%. Alternatively, the Ig fractions of these patients or of pooled normal human plasma (NHP) were added to 5% NHS in an equal volume. Data were collected from three independent experiments; means are given with error bars showing SDs. Statistical analysis for test samples compared with NHP Ig from $t = 20$ to $t = 60$ as calculated using two-way analysis of variance is given for the patient Igs only: **$P < 0.01$, ***$P < 0.001$, ns not significant. Heat-inactivated NHS ($\Delta$NHS) and an NHS sample from which guinea pig serum were omitted during the second part of the assay ($\text{no step 2}$) served as negative controls for the first and second steps, respectively. Hemolysis levels are given as percentage of full lysis of erythrocytes in water.

A limitation of our assay’s serum approach is that it does not directly give insight into the nature (autoantibody or genetic variant) and mechanism of the convertase-stabilizing factor present in the patient’s serum. When clinically relevant, e.g., to evaluate whether B cell-depleting therapy may be indicated, this nature can be dissected by assessing stabilizing activity in purified Ig fractions, screening for FHaAb, and genetic analysis, as we described in this study.

We have shown that the convertase-stabilizing activity in patients P24–P27 resides in the Ig fraction (Figure 5), indicating the presence of stabilizing autoantibodies. For these patients, we also described the convertase activity during disease progression. In three of them (P24, P27, and P25; Figures 4A–C), convertase-stabilizing factors were present in all samples taken during the different stages of disease. By contrast, the stabilizing Igs detected in the acute phase of P26 became undetectable in remission (Figure 4D). These data are in line with several previous reports on C3G/membranoproliferative glomerulonephritis cohorts that allow easy screening for any factor directly or indirectly affecting convertase stability, not limited to C3NeF. Moreover, convertases are studied in their physiological surroundings where (negative and positive) complement regulators and other serum factors are present to interact with the convertases. For this reason, we believe our method is particularly suited to detect functionally relevant C3NeF and other stabilizing factors. The assay is also well suited to screen for convertase-influencing factors in other pathologies associated with complement dysregulation, such as age-related macular degeneration, immune complex-mediated membranoproliferative glomerulonephritis, postinfectious glomerulonephritis, systemic lupus erythematosus, and acquired partial lipodystrophy (30, 55, 56). However, future research may focus on further adaptation of the assay with human (renal) cells as platforms for convertase assembly, since they best reflect physiological circumstances regarding the expression of membrane-bound inhibitors and binding places for the soluble inhibitor FH.
showed a fluctuation in C3NeF activity over disease course in at least one-third of all positive patients (15, 20, 34). Whereas in some patients C3NeF were persistently present, in others they appeared or disappeared during follow-up. Above that, in these studies no correlation was found between C3NeF presence, plasma C3 levels, and clinical recovery. More longitudinal studies are needed to further examine the contribution of C3NeF to disease progression and to establish its value as a (prognostic) disease biomarker.

Even though we did not find patients positive for FHaAb in the described cohort, it is important to screen for these autoantibodies, since they may also indirectly increase convertase stability by impairing the convertase regulation by FH (37). FHaAb occur in around 10% of C3G cases and have different characteristics than those occurring in aHUS cases, for example, regarding their target epitope on FH and their pathological consequences (57, 58). Moreover, FHaAb have been previously reported in simultaneous presence of C3NeF, but the combined role of these two autoantibodies in mediating AP activation remains unclear and requires further investigation (58).

Increased stability of convertases cannot only be caused by autoantibodies but may also be due to genetic aberrations. We confirmed that the stabilizing C3NeF-like activity detected in the aHUS patient with known FB mutation (p.Lys323Glu) is due to its aberrant FB activity: increased convertase stability in serum segregated with the FB mutation in both affected and non-affected family members (Figure 6B), while the purified Igs from this patient did not support convertase stabilization (Figure 6C). This increased convertase half-life associated with the FB mutation is in line with previous functional assays showing that this particular variation causes resistance of the C3 convertase to decay by FH and DAF (41). The fact that a carrier of the mutation shows increased convertase stability in our assay while not being affected with aHUS is supportive for the theory of the incomplete penetrance of mutations in complement genes in aHUS. This theory postulates that multiple (environmental) triggers are required for the actual development of the disease (24). Thus, we show that our assay is also capable as a functional assay for identifying gain-of-function mutations in the building blocks of the AP convertase.
In conclusion, we present optimization of an efficient, robust, and reliable assay for detection and characterization of convertase-stabilizing factors (C3NeF and some genetic changes) in patients with complement-mediated renal diseases and for monitoring these patients during treatment. This assay can be used for studying the role of these factors in the pathophysiology of C3G or related disorders and may contribute to the development of more personalized treatment strategies.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the appropriate version of the Declaration of Helsinki. All subjects gave written informed consent, and the protocol was approved by the ethical committee of the Radboud University Medical Center (FH 06979).

AUTHOR CONTRIBUTIONS

Concept of the study: NK, MO, AB, EV, and LH. Design of the experiments: MM, MO, EV, and LH. Experimental work: MM and SK. Data analysis: MM, NK, EV, and LH. Collection and characterization of clinical samples (including genetic data): NK, EV, and LH. Manuscript writing: MM. All the authors approved the manuscript.

ACKNOWLEDGMENTS

This study was performed on behalf of the COMBAT Consortium. This is an interuniversity collaboration in the Netherlands that is formed to study basic mechanisms, assay development, and therapeutic translation of complement-mediated renal diseases. Principal investigators are (in alphabetical order): S. Berger (Department of Internal Medicine-Nephrology, University Medical Center Groningen, Groningen, Netherlands), J. van den Born (Department of Internal Medicine-Nephrology, University Medical Center Groningen, Groningen, Netherlands), P. Gros (Department of Chemistry, Utrecht University, Utrecht, Netherlands), L. van den Heuvel (Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, Netherlands), N. van de Kar (Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, Netherlands), C. van Kooten (Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands), M. Seelen (Department of Internal Medicine-Nephrology, University Medical Center Groningen, Groningen, Netherlands), A. de Vries (Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands). The authors thank all physicians for sharing patient samples and providing the clinical data needed: Dr. A. Bouts and Dr. M. Oosterveld, Academic Medical Center, Amsterdam, Netherlands; Dr. V. Gracchi, University Medical Center Groningen, Groningen, Netherlands; Prof. Dr. E. Levchenko, University Hospitals Leuven, Leuven, Belgium; Dr. A. de Vries, Leiden University Medical Center, Leiden, Netherlands; Prof. Dr. J. Wetzels, Radboud University Medical Center, Nijmegen, Netherlands; Dr. Y. Konijnendonk, St Jansdal Hospital, Harderwijk, Netherlands; Dr. J. van der Deure, Deventer Hospital, Deventer, Netherlands; Dr. M. Keijzer-Veen and Dr. M. Lilien, Wilhelmina Children’s Hospital, Utrecht, Netherlands; Dr. A. van Wijk and Dr. A. Bökenkamp, VU University Medical Center, Amsterdam, Netherlands; Dr. K. Cransberg and Dr. E. Durresteijn, Erasmus Medical Center, Rotterdam, Netherlands. A special thanks to Dr. Roel Kurbards (Radboud University Medical Center, Nijmegen, Netherlands) for his contribution to the phenotyping of patients.

FUNDING

This work was supported by grants from the Dutch Kidney Foundation (13OCA27 COMBAT Consortium, 13O1116, KFB 11.007, IP 10.22, 16OJKK01), the European Renal Association—European Dialysis and Transplantation Association (grants ERA STF 138–2013, ERA LTF 203–2014), the National Science Centre Poland (grants 2015/18/M/NZ6/00334 and 2014/14/E/ NZ6/00182), and the European Society for Pediatric Nephrology (grant 2014.03).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00612/full#supplementary-material.

REFERENCES

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 11(9):785–97. doi:10.1038/ni.1923
2. Walport MJ. Complement. First of two parts. Nat Rev Immunol (2001) 1(10):529–50. doi:10.1038/35095000
3. Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology (2016) 221(6):747–51. doi:10.1016/j.imbio.2015.04.006
4. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol (2015) 6:262. doi:10.3389/fimmu.2015.00262
5. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med (2008) 12(4):1074–84. doi:10.1111/j.1749-6632.2008.00350.x
6. Harrison RA. The properdin pathway: an alternative activation pathway or a "critical amplification loop" for C3 and C5 activation? Semin Immunopathol (2018) 40(1):15–35. doi:10.1007/s00281-017-0661-x
7. Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med (2015) 277(3):294–305. doi:10.1111/j.1365-2796.2014.12338
8. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 9(10):729–40. doi:10.1038/nri2620
9. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 190(8):3831–8. doi:10.4049/jimmunol.1203487
10. Zipfel PF, Heinen S, Jozisi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol (2006) 43(1–2):97–106. doi:10.1016/j.molimm.2005.06.015
11. Halors VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev (2008) 223:300–16. doi:10.1111/j.1600-065X.2008.00641.x
12. Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis (2015) 66(2):359–75. doi:10.1016/j.ajkd.2015.03.040
13. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 151(1):1–13. doi:10.1111/j.1365-2249.2007.

14. Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, et al. The role of complement in C3 glomerulopathy. Mol Immunol (2015) 67(1):21–30. doi:10.1016/j.molimm.2015.03.012

15. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 82(4):454–64. doi:10.1038/kji.2012.63

16. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int (2013) 84(6):1079–89. doi:10.1038/kji.2013.377

17. Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr nephrol (2017) 32(1):43–57. doi:10.1007/s00467-015-3310-4

18. Daha MR, Fearon DT, Austen KE. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 116(1):1–7.

19. Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 7(2):265–74. doi:10.2215/CJN.07990811

20. Schwartz R, Rother V, Anders D, Grett N, Scharer K, Kirschfink M. Comparative analysis in children with idiopathic membranoproliferative glomerulonephrit: a long-term follow-up. Pediatr Allergy Immunol (2001) 12(3):166–72. doi:10.1034/j.1399-3038.2001.012003166.x

21. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteome profile, treatment, and follow-up. Kidney Int (2012) 82(4):465–73. doi:10.1038/kji.2012.212

22. Fremeaux-Bacchi V, Fakhouri F, Garmeri A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 8(4):1554–62. doi:10.2215/CJN.04760512

23. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 31(6):E1445–60. doi:10.1002/humu.21256

24. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gasbarrino G, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 5(10):1844–59. doi:10.2215/CJN.02210310

25. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 361(17):1676–87. doi:10.1056/NEJMr092818

26. Legendre CM, Licht C, Musa P, Greenbaum LA, Babu S, Bedford JS, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2010) 362(23):2169–81. doi:10.1056/NEJMoa1008981

27. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of ecu-lizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 8(11):643–57. doi:10.1038/nrneph.2012.214

28. Le Quintrec M, Lapeyreque AL, Lionet A, Seller-Leclerc AL, Delmas Y, Baudouin V, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis (2016). doi:10.1053/j.ajkd.2017.11.019

29. Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost (2014) 40(4):472–7. doi:10.1055/s-0034-1375299

30. Prohaszka Z, Nilsson B, Fakhouri F, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis. Pediatr Nephrol (2017) 32(1):206–13. doi:10.1007/s00467-016-3268-72. doi:10.1007/s00467-013-3268-7

31. Pescosolido E, Cortina P, Manunta M, Andreucci VE. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis. Clin Nephrol (1982) 18(5):240–6.
53. Chen Q, Muller D, Rudolph B, Hartmann A, Kuwertz-Broking E, Wu K, et al. Combined C3b and factor B autoantibodies and MPGN type II. *N Engl J Med* (2011) 365(24):2340–2. doi:10.1056/NEJMct1107484

54. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. *Clin J Am Soc Nephrol* (2009) 4(1):22–32. doi:10.2215/cjn.03480708

55. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. *Immunobiology* (2012) 217(11):1034–46. doi:10.1016/j.imbio.2012.07.021

56. Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, et al. Complement activation by (auto-) antibodies. *Mol Immunol* (2011) 48(14):1656–65. doi:10.1016/j.molimm.2011.04.024

57. Blanc C, Togarsimalmath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. *J Immunol* (2015) 194(11):5129–38. doi:10.4049/jimmunol.1402770

58. Durey MA, Sinha A, Togarsimalmath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. *Nat Rev Nephrol* (2016) 12(9):563–78. doi:10.1038/nrneph.2016.99

**Conflict of Interest Statement:** NK is a member of the international aHUS Advisory Board of Alexion. The remaining co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Michels, van de Kar, Obrój, Blom, van Kraaij, Volokhina and van den Heuvel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*